Renovaro (RENB) said Friday that it received an email from Predictive Oncology (POAI) on April 3 terminating the companies' merger transaction.
Renovaro said that Predictive Oncology remains bound by the original agreement and must sign an exclusive license agreement as outlined in the binding documents.
Failure to do so will result in "legal remedies to recover all its damages and/or seek additional remedies to fully redress the breaches," Renovaro said.
Renovaro shares were down by nearly 13% in recent trading, while Predictive Oncology was down 7%.
Predictive Oncology did not immediately respond to a request for comment from MT Newswires.
Price: 0.40, Change: -0.07, Percent Change: -14.27
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.